BAGSVAERD, Denmark, March 25, 2015 (GLOBE NEWSWIRE) -- Novo Nordisk today announced headline results from the final phase 3a trials for faster-acting insulin aspart, onset® 1 and onset® 2. The trials investigated the efficacy and safety of faster-acting insulin aspart compared with NovoRapid® (insulin aspart) in a basal-bolus regimen in people with type 1 and type 2 diabetes, respectively.
For further information
Media: | ||
Mike Rulis | +45 3079 3573 | mike@novonordisk.com |
Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com |
Investors: | ||
Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com |
Company Announcement No 22 2015
Company Announcement No 22 2015 http://hugin.info/2013/R/1906174/678581.pdf
HUG#1906174